You are now
leaving this site

If you'd like to stay, click CANCEL.
X

APDS Expert Locator Tool

A tool enabling patients and caregivers to find medical professionals with expertise in diagnosing and treating APDS. Additionally, APDS experts can list their information in the locator tool.

Reminder tone

Download the free Joenja reminder tone, to set and receive an audio reminder when it’s time for you to take your Joenja tablet.

Get to know APDS Assist

Find out more about how APDS Assist works to support you and your patients by watching this short video.

Joenja brochure for patients and caregivers

A brochure containing important information for patients and caregivers to know about Joenja, including how and when to take Joenja tablets, what to expect with Joenja, as well as information about patient support services.

Indications and Usage

JOENJA® (leniolisib) is a kinase inhibitor indicated for the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in adult and pediatric patients 12 years of age and older.

Important Safety Information

Verify pregnancy status in females of reproductive potential prior to initiating treatment with JOENJA.

Indications and Usage

JOENJA® (leniolisib) is a kinase inhibitor indicated for the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in adult and pediatric patients 12 years of age and older.

Important Safety Information

Verify pregnancy status in females of reproductive potential prior to initiating treatment with JOENJA.

JOENJA may cause fetal harm when administered to a pregnant woman. Advise patients of the potential risk to a fetus and to use highly effective methods of contraception during treatment with JOENJA and for 1 week after the last dose of JOENJA.

Live, attenuated vaccinations may be less effective if administered during JOENJA treatment.

Use of JOENJA in patients with moderate to severe hepatic impairment is not recommended. There is no recommended dosage for patients weighing less than 45 kg.

The most common adverse reactions (incidence >10%) seen in clinical trials were headache, sinusitis, and atopic dermatitis.

Seven (33%) patients receiving JOENJA developed an absolute neutrophil count (ANC) between 500 and 1500 cells/microL. No patients developed an ANC <500 cells/ microL and there were no reports of infection associated with neutropenia.

Before prescribing JOENJA, please read the full Prescribing Information.